Infekcje i urazy spowodowane zanieczyszczonymi endoskopami: co musisz wiedzieć

Flexible endoscope outbreaks can cause CRE, pseudomonas, or other serious infections after ERCP or similar procedures. This overview explains injury types and why device reprocessing is central to litigation.

Reusable endoscopes are used millions of times each year because they make diagnosis and therapy less invasive. When reprocessing fails—or when device features make cleaning harder than it looks on paper—patients can face serious infections and downstream complications. This article focuses on the clinical and practical risks tied to contaminated scopes, why Olympus duodenoscopes draw repeated scrutiny, what 2025 safety communications changed, and how people researching a medical scope infection lawsuit, endoscope infection claim, or endoscope injury lawsuit usually begin. It is general information only, not medical or legal advice.

Introduction: Endoscope-Related Infections and Injuries

An endoscope can be a life-saving tool, but it is also a reusable instrument that contacts mucosa, enters channels, and may encounter blood and bioburden. Facilities are supposed to clean and disinfect (or sterilize) scopes between patients using manufacturer instructions for use (IFU) and professional standards. When contamination persists—because of soil in tiny channels, damaged components, delayed precleaning, or process breakdowns—the next patient may be exposed to bacteria or other pathogens.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

Olympus is a major manufacturer of endoscopes and duodenoscopes. Duodenoscopes used during ERCP are especially complex because of moving parts at the distal tip (often described as an “elevator” mechanism) that help steer instruments into the bile and pancreatic ducts. That complexity matters because plaintiffs in scope litigation frequently argue that certain designs and instructions did not adequately control cross-patient infection risk. Whether any particular infection was “caused by” a scope is a fact-specific question requiring records—not something a webpage can answer.

Types of Infections and Injuries Linked to Contaminated Endoscopes

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.

Why Olympus Endoscopes Are Particularly Risky (Design and Real-World Use)

It is not that Olympus is the only manufacturer discussed in endoscopy safety debates—it is that duodenoscopes, including many Olympus models, combine high procedural value with hard-to-clean mechanical features.

According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

Recent Safety Notices, Field Corrections, and Recalls (2025 Focus)

Regulatory databases and manufacturer communications in 2025 continued to emphasize duodenoscope reprocessing as an active risk-management problem rather than a solved one. In October 2025, Olympus issued urgent field safety notices affecting multiple duodenoscope models (commonly listed notices referenced models such as TJF-Q190V, TJF-Q290V, and TJF-Q170V in public summaries). Public descriptions of those communications often highlight themes such as:

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

• Tightening expectations for how quickly manual cleaning must begin after a procedure ends (for example, replacing longer delay windows with a shorter maximum time before cleaning starts).
• Emphasizing that delayed cleaning can increase the risk that dried debris will not be fully removed, which can raise microbial contamination concerns.
• Updating inspection expectations for distal tip components, sometimes referencing enhanced visual inspection practices compared with older “naked eye” approaches.

Separately, FDA recall entries and medical device correction postings periodically list Olympus scope actions tied to adhesive integrity, seal concerns, or other issues that could theoretically increase contamination risk if fluids intrude into internal spaces. The lesson for patients is practical: safety is not only “the hospital’s job” or “the company’s job”—it is a system problem where labeling, training, device condition, and timing all interact.

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

For a running list of litigation-facing updates, see recent Olympus endoscope lawsuit news and safety developments and FDA’s medical device recall and safety communication pages for primary sources.

Legal Claims and How to Pursue Compensation

People search for a medical scope infection lawsuit when they believe a serious infection or injury may be connected to a procedure and device pathway. Civil claims may include product liability theories (design defect, failure to warn, inadequate instructions) and negligence theories, depending on state law and the evidence.

According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.

FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.

What Victims Should Do Next

If you suspect you were harmed after a scope procedure, consider taking these practical steps:

According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.

1. Get appropriate medical care and follow your clinician’s plan; your health comes first.
2. Preserve records: procedure reports, discharge summaries, lab and culture results, antibiotic lists, and any letters about infection control or scope notifications.
3. Write a simple timeline: procedure date, first fever or symptoms, ER visits, admissions, and diagnoses.
4. Request a confidential case review if you want to understand options: use Olympus endoscope case review or contact us.

Frequently Asked Questions

Q: What are common infections caused by contaminated endoscopes?

Claims and outbreak reports often discuss serious bacterial infections, including resistant organisms; sepsis; and sometimes secondary complications. The relevant infection for any person depends on cultures and clinical course.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

Q: How can I tell if I was affected by a defective Olympus endoscope?

You may not be able to tell from symptoms alone. Clues include positive cultures after procedure, infection-control letters, documentation identifying a scope brand/model, or facility notices. An attorney-led review focuses on records.

Q: What legal options are available for victims of endoscope-related infections?

Depending on facts, some people pursue civil claims against device manufacturers and sometimes other defendants. Options and strategy depend on state law and evidence.

According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.

Q: How long do I have to file a lawsuit?

Deadlines vary by state and claim type. Do not guess—speak with a licensed attorney promptly because missing a deadline can bar a claim.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

For compensation frameworks at a higher level, see legal rights and compensation in Olympus endoscope lawsuits.

The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.

Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney–client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.